HeartFlow
Convertible Note in 2025
HeartFlow, Inc. is a medical technology company that specializes in non-invasive solutions for coronary artery disease detection. Founded in 2007 and based in Redwood City, California, with additional offices in Portland, Austin, London, and Tokyo, the company offers its HeartFlow Analysis, which utilizes data from standard computerized tomography scans to create personalized three-dimensional models of a patient's heart. This analysis helps clinicians evaluate the impact of blockages on blood flow, facilitating informed treatment decisions while minimizing the need for invasive testing. HeartFlow's technology integrates over two decades of scientific research with advancements in artificial intelligence, making its HeartFlow FFRCT Analysis available in the United States, Canada, Europe, the United Kingdom, and Japan.
HeartFlow
Series F in 2023
HeartFlow, Inc. is a medical technology company that specializes in non-invasive solutions for coronary artery disease detection. Founded in 2007 and based in Redwood City, California, with additional offices in Portland, Austin, London, and Tokyo, the company offers its HeartFlow Analysis, which utilizes data from standard computerized tomography scans to create personalized three-dimensional models of a patient's heart. This analysis helps clinicians evaluate the impact of blockages on blood flow, facilitating informed treatment decisions while minimizing the need for invasive testing. HeartFlow's technology integrates over two decades of scientific research with advancements in artificial intelligence, making its HeartFlow FFRCT Analysis available in the United States, Canada, Europe, the United Kingdom, and Japan.
Karyopharm Therapeutics
Post in 2022
Karyopharm Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Newton, Massachusetts, specializing in the discovery, development, and commercialization of novel drugs targeting nuclear export mechanisms for the treatment of cancer and other diseases. Its lead drug, XPOVIO (selinexor), is an approved treatment for multiple hematologic malignancies, particularly in patients with heavily pretreated multiple myeloma. The company is advancing several clinical trials for its products, including BOSTON and STORM for multiple myeloma, SADAL for relapsed or refractory diffuse large B-cell lymphoma, and SEAL for liposarcoma. Karyopharm is also exploring treatments for endometrial cancer and glioblastoma multiforme. Additionally, the company has partnerships to investigate low-dose selinexor for hospitalized COVID-19 patients and collaborates with the National Cancer Institute for cancer therapy evaluations. Karyopharm utilizes a proprietary platform to develop small molecule drugs that modulate key cellular pathways involved in cancer and inflammation.
Mineralys Therapeutics
Series B in 2022
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.
DNA Script
Series C in 2022
DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life science and human health through innovative technology. The company has developed a unique enzymatic process that allows for the production of synthetic DNA using natural enzymes. This technology underpins their benchtop DNA printer, SYNTAX, which enables laboratories to synthesize their own oligonucleotides. By doing so, DNA Script provides researchers with greater control over their workflows, facilitating faster access to essential genomic materials for various applications in molecular biology and genomics. This capability accelerates experimentation and supports the development of new therapeutics, positioning DNA Script as a key player in the biotechnology sector.
Acrivon Therapeutics
Series B in 2021
Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on precision oncology, developing therapeutics that target challenging cancer types without straightforward single-gene mutations. The company employs a proteomics-based platform to identify patients whose tumors are likely to respond to specific treatments. Acrivon's pipeline includes ACR-368, also known as prexasertib, which is currently in Phase 2 trials, alongside preclinical programs aimed at key components of DNA damage response and cell cycle regulation, such as the WEE1 and PKMYT1 proteins. Acrivon seeks to expedite the development of both in-licensed clinical-stage assets and its internally developed programs through accelerated registration trials, aiming to enhance treatment success in oncology.
Imperative Care
Series D in 2021
Imperative Care, Inc. is dedicated to enhancing the speed and effectiveness of acute stroke treatment through innovative medical technologies. Founded in 2015 and based in Campbell, California, the company has developed a range of solutions aimed at addressing critical needs in stroke care. Among its offerings is the Large Distal Platform, a large diameter catheter designed to reach treatment sites for both ischemic and hemorrhagic strokes. Complementing this is the ZOOM Aspiration System, a comprehensive solution that works in conjunction with the Large Distal Platform and includes various trackable reperfusion catheters for effective clot removal. By advancing stroke treatment technologies, Imperative Care aims to improve patient outcomes and optimize recovery processes for those affected by strokes.
Ikena Oncology
Series B in 2021
Ikena Oncology is a biotechnology company based in Boston, Massachusetts, focused on developing innovative therapies for cancer treatment. The company specializes in biomarker-driven and precision therapies that target specific mechanisms involved in cancer growth, spread, and resistance. Its product pipeline includes several candidates such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-930, an oral small-molecule inhibitor of the TEAD transcription factor in the Hippo signaling pathway. Additionally, Ikena is exploring a kynurenine-degrading enzyme with IK-412 and other discovery-stage programs targeting various oncogenic pathways. Established in 2016, Ikena Oncology aims to address unmet medical needs through a combination of chemistry, translational science, and patient-centered drug development.
Paige, founded in 2017 by Thomas Fuchs and colleagues from Memorial Sloan Kettering Cancer Center, specializes in computational pathology products that enhance cancer diagnostics. The company has developed a platform utilizing advanced deep learning algorithms to improve diagnostic stratification and cancer detection, particularly for breast and prostate cancers. This innovative technology aims to empower patients and their care teams to make informed treatment decisions by providing pathologists with critical insights for more accurate diagnoses. Paige's user-friendly platform minimizes the burden on IT resources while ensuring patient safety and data privacy. As a pioneer in the field, Paige has achieved FDA breakthrough designation for its computational pathology products, positioning itself at the forefront of transforming pathology workflows and increasing diagnostic confidence.
Paige, founded in 2017 by Thomas Fuchs and colleagues from Memorial Sloan Kettering Cancer Center, specializes in computational pathology products that enhance cancer diagnostics. The company has developed a platform utilizing advanced deep learning algorithms to improve diagnostic stratification and cancer detection, particularly for breast and prostate cancers. This innovative technology aims to empower patients and their care teams to make informed treatment decisions by providing pathologists with critical insights for more accurate diagnoses. Paige's user-friendly platform minimizes the burden on IT resources while ensuring patient safety and data privacy. As a pioneer in the field, Paige has achieved FDA breakthrough designation for its computational pathology products, positioning itself at the forefront of transforming pathology workflows and increasing diagnostic confidence.
Claret Medical
Series C in 2017
Claret Medical, Inc. is a medical device company specializing in cerebral vascular protection systems designed to mitigate the risk of stroke during transcatheter aortic valve implantation and other endovascular procedures. Established in 2009 and headquartered in Santa Rosa, California, the company's flagship products include the Claret Medical Sentinel Cerebral Protection System and the Claret Medical Montage, both of which serve as embolic protection devices. These systems utilize small catheters, which are inserted through an artery in the patient's arm and positioned near the heart, to capture and remove embolic debris that may be dislodged during procedures. By preventing this debris from entering the cerebral vascular system, Claret Medical's products aim to enhance patient safety during high-risk cardiovascular interventions. The company operates as a subsidiary of Boston Scientific Corporation.
PreemaTEX
Seed Round in 2015
PreemaTEX is the developer of an innovative, high value diagnostic tests focused on assessing a woman’s risk for preterm delivery early in pregnancy.
ReShape Medical
Series D in 2015
ReShape Medical Inc. specializes in non-surgical weight loss solutions aimed at individuals with mild to moderate obesity, specifically those with a Body Mass Index (BMI) of 30 to 40. The company offers the ReShape Integrated Dual Balloon System, which consists of two intragastric balloons that are placed in the stomach and filled with saline. This system is intended to assist patients in losing weight when combined with a medically supervised diet and exercise program. The procedure is designed for adults who have not achieved significant weight loss through diet and exercise alone. ReShape Medical also provides other weight management solutions, including the FDA-approved Lap-Band System and the investigational ReShape Vest System, which aim to support patients in their weight loss journeys while minimizing the need for invasive surgical procedures. Founded in 2005 and based in San Clemente, California, ReShape Medical operates as a subsidiary of EnteroMedics Inc.
HLS Therapeutics
Venture Round in 2015
HLS Therapeutics Inc is a specialty pharmaceutical company that focuses on the acquisition and commercialization of branded pharmaceutical products primarily in North America. The company is committed to managing the life cycles of these products after their exclusivity, ensuring that essential treatments remain accessible to patients and caregivers. HLS Therapeutics offers a range of products, including Clozaril and Vascepa, and generates revenue mainly through product sales, supplemented by royalties. Operating in Canada, the United States, and other international markets, HLS Therapeutics plays a crucial role in maintaining the availability of trusted medications.
Natera, Inc. is a diagnostic and research company specializing in genetic testing services, particularly in the areas of preconception and prenatal diagnostics. Founded in 2003 and headquartered in San Carlos, California, Natera offers a range of products including the Panorama non-invasive prenatal test, which screens for chromosomal abnormalities in fetuses, and Vistara, a test for single-gene mutations. Additionally, the company provides Horizon carrier screening to assess carrier status for various genetic diseases, and Spectrum, which analyzes genetic conditions during in vitro fertilization. Natera's Anora product analyzes fetal chromosomes to understand miscarriage causes, while its non-invasive paternity tests determine parentage through fetal DNA analysis. The company's Signatera technology focuses on circulating tumor DNA to monitor cancer recurrence. Natera distributes its products through a direct sales force and a network of approximately 100 laboratory and distribution partners, both domestically and internationally. The company collaborates with BGI Genomics to develop genetic testing assays and has partnered with Foundation Medicine for personalized cancer monitoring assays.
Kellbenx Inc. is a biotechnology company established in 2010 and headquartered in Great River, New York. The company specializes in the development of non-invasive prenatal diagnostics (NIPDX) aimed at identifying specific genetic and heritable disorders. Kellbenx's innovative approach utilizes intact DNA to detect aneuploidies and various genetic abnormalities, thereby enhancing women's healthcare. By focusing on non-invasive methods, the company aims to provide safer and more effective diagnostic solutions for expectant mothers.
Careview Communications
Post in 2011
CareView Communications develops a proprietary network system designed for healthcare facilities, utilizing existing coaxial cable infrastructure to enhance patient safety and operational efficiency. The company's offerings include real-time patient monitoring, which features Virtual Bed Rails and Virtual Chair Rails to prevent falls proactively. Additionally, CareView's bed management program provides a real-time dashboard for tracking bed status, aiding in patient placement and preventing overcrowding. The CareView Mobile application allows nursing staff to manage patient care conveniently from mobile devices, facilitating efficient communication through voice, text, and email. The company also enhances patient satisfaction through entertainment features and a patient education portal, providing easy access to informative resources for patients and their families. Overall, CareView Communications aims to improve hospital communications and operations while fostering a safer and more satisfying patient experience.
Sadra Medical
Venture Round in 2010
Sadra Medical is focused on developing innovative therapies for the treatment of aortic valve disease, particularly through minimally invasive alternatives to traditional surgical valve replacement. The company offers transcatheter aortic valve replacement systems, including the Lotus valve, which is a bovine tissue tri-leaflet bioprosthetic aortic valve supported by a nitinol stent structure. Additionally, Sadra Medical provides the Lotus delivery catheter, designed for the guidance and placement of the Lotus valve. With aortic valve stenosis affecting approximately 3 million people in the U.S. and a significant portion remaining untreated, Sadra Medical aims to address this unmet clinical need by enhancing treatment options and improving patient care while reducing the risks associated with open-heart surgery.
Access Closure
Venture Round in 2010
Access Closure, Inc. is a medical device company based in Mountain View, California, specializing in vascular closure solutions for interventional and diagnostic procedures. Founded in 2002, the company offers innovative products, including the Mynx delivery system. This device effectively seals arteriotomy sites using a water-soluble and extravascular sealant, which expands within the tissue by absorbing blood and subcutaneous fluids. Access Closure aims to simplify and enhance the process of vascular closure, addressing the complexities associated with these medical procedures.
ApaTech
Venture Round in 2008
ApaTech Ltd. is an ortho-biologics company based in Elstree, United Kingdom, specializing in synthetic bone repair materials for surgical applications. Founded in 2001, the company develops innovative products such as Actifuse, a synthetic bone graft that enhances bone formation and is particularly effective for small void filling and spinal fusion. Additionally, ApaTech offers ApaPore, a porous hydroxyapatite grafting solution designed for the revision of failed total joint arthroplasties and the treatment of bone defects. The Actifuse MIS Bone Graft Delivery System provides precise delivery and placement for a range of surgical procedures, including open and minimally invasive operations. ApaTech distributes its products through a network of partners across multiple countries, including those in Europe and Australia. The company also maintains operations in London, Foxborough, Massachusetts, and Berlin, Germany.
Paradigm Spine
Series E in 2008
Paradigm Spine, LLC is a privately-held medical device company based in New York, specializing in the design, development, and marketing of innovative solutions for spinal diseases. The company focuses on non-fusion spinal implant technology, offering a range of minimally invasive products aimed at treating conditions such as lumbar spinal stenosis and age-related spinal deformities. Key offerings include the Coflex interspinous implant, which is used for facet arthrosis and decompression procedures, as well as the DSS system, a minimally-invasive pedicle-screw based solution. Paradigm Spine emphasizes the development of surgeon-centric and indication-specific products that preserve motion and support natural anatomical function, catering to spine specialists worldwide. Founded in 2002, the company was previously known as Spine Motion, LLC before rebranding in 2005.
Corindus designs, manufactures, and commercializes remote robotic systems for interventional procedures. The company's products include CorPath, which enables physicians to perform catheterization procedures from a remote location away from the radiation zone. The company was formerly known as Navicath, Ltd. Corindus was founded in 2002 and is based in Waltham, Massachusetts.
HeartFlow
Seed Round in 2008
HeartFlow, Inc. is a medical technology company that specializes in non-invasive solutions for coronary artery disease detection. Founded in 2007 and based in Redwood City, California, with additional offices in Portland, Austin, London, and Tokyo, the company offers its HeartFlow Analysis, which utilizes data from standard computerized tomography scans to create personalized three-dimensional models of a patient's heart. This analysis helps clinicians evaluate the impact of blockages on blood flow, facilitating informed treatment decisions while minimizing the need for invasive testing. HeartFlow's technology integrates over two decades of scientific research with advancements in artificial intelligence, making its HeartFlow FFRCT Analysis available in the United States, Canada, Europe, the United Kingdom, and Japan.
Paradigm Spine
Series D in 2007
Paradigm Spine, LLC is a privately-held medical device company based in New York, specializing in the design, development, and marketing of innovative solutions for spinal diseases. The company focuses on non-fusion spinal implant technology, offering a range of minimally invasive products aimed at treating conditions such as lumbar spinal stenosis and age-related spinal deformities. Key offerings include the Coflex interspinous implant, which is used for facet arthrosis and decompression procedures, as well as the DSS system, a minimally-invasive pedicle-screw based solution. Paradigm Spine emphasizes the development of surgeon-centric and indication-specific products that preserve motion and support natural anatomical function, catering to spine specialists worldwide. Founded in 2002, the company was previously known as Spine Motion, LLC before rebranding in 2005.